Quince Therapeutics, Inc. announced that its pivotal Phase 3 NEAT clinical trial for EryDex in Ataxia-Telangiectasia (A-T) has enrolled 46 participants to date. This progress means enrollment is nearing the 50% mark for the study.
The company expects screening and randomization to accelerate in the coming weeks due to the activation of several new geographic regions and clinical sites. This acceleration is crucial for maintaining the trial's timeline.
Quince Therapeutics reiterated its expectation to complete enrollment during the second quarter of 2025 and to report topline results before the end of 2025. This update provides a clear indication of the trial's advancement towards its key milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.